Ventas Inc Dossier - Source-backed chat

Ventas Inc

VTRNYSE

SectorReal Estate

IndustryHealth Care REITs

Beta (adjusted)0.80

Intrinsic Value $55.44median of 1 methodbased on filings through 30 Jun 2026

Market Price $85.02Price as of 30 Sep 2026

OvervaluedIntrinsic value is 35% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $43.6B

Enterprise Value $56.4B

Shares Outstanding 501.9M diluted

Next Earnings Date27 Oct 2026

Last ex-dividend30 Jun 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Ventas entered the second half of 2026 with strong operating momentum: second-quarter SHOP same-store cash NOI increased 16.3%, normalized FFO per share rose 9% year over year to $0.97, FY 2026 normalized FFO guidance was raised to $3.85-$3.90, and net debt to further adjusted EBITDA improved to 4.7x. Management also raised expected 2026 senior-housing investment volume to $4.5 billion after completing $3.4 billion year to date. However, the August 28 closing price of $91.81 already reflects substantial optimism, while rapid equity-funded expansion creates dilution and integration risk. The probability-weighted scenario value is approximately $93.50, supporting a Hold rather than a more aggressive recommendation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets22 analysts · as of 18 Aug 2026

Low · most bearish analyst$86.00

Mean target$100.45

High · most bullish analyst$113.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$86.0019%

SHOP growth falls below 8%, operating-margin gains fade, acquisitions integrate more slowly than expected, or capital-market conditions push leverage above 5.5x and normalized FFO below the current guidance floor. These outcomes would weaken the earnings-growth narrative and support a $72 twelve-month research scenario.

Base CaseCentral scenario

$100.4556%

Matches the consensus mean

Ventas delivers normalized FFO within the current $3.85-$3.90 range, SHOP growth moderates from the second-quarter pace but remains healthy, and acquisition contributions offset equity dilution while leverage stays near current levels.

Bull CaseUpside scenario

$113.0025%

SHOP growth remains in double digits, occupancy and margins continue expanding, the $4.5 billion investment program is completed on attractive terms, leverage remains controlled, and normalized FFO guidance is raised again. Continued execution and favorable senior-housing supply-demand conditions support a $110 twelve-month research scenario.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Second-quarter SHOP same-store cash NOI grew 16.3%, supported by 8.6% same-store cash operating revenue growth, approximately 300 basis points of average occupancy growth and 210 basis points of margin expansion.
Management raised FY 2026 normalized FFO guidance to $3.85-$3.90 per share and increased expected senior-housing investment volume to $4.5 billion after completing $3.4 billion year to date.
Net debt to further adjusted EBITDA improved to 4.7x, and reported liquidity of $4.9 billion provides capacity to execute the investment program.

Key Investment Risks

Growth is materially equity-funded: Ventas settled 31.4 million forward-sale shares for $2.6 billion of gross proceeds year to date and reported another $1.6 billion of unsettled equity forwards, creating per-share dilution risk.
The accelerated acquisition program increases underwriting, integration and operator-execution risk; anticipated returns and synergies may not be realized on schedule.
Ventas remains exposed to interest rates, labor costs, third-party operator performance, healthcare regulation and access to debt and equity capital.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.